论文部分内容阅读
在心肌梗塞溶栓治疗(TTMI)第二阶段实验中,患者接受静脉注入重组组织型纤溶酶原激活因子(rt-PA)并随机行保守性或侵入性处理。本研究对1434例适于应用β-阻滞剂治疗的患者进行即刻与延迟给予β-阻滞剂治疗的效果评价,其中随机将720例分为即刻给药组,714例为延迟给药治疗组。即刻治疗组在应用 rt-PA2小时内给予美多心安(每次5mg静注,6分钟以上注完,间隔2分钟一次,至总量为15mg,继后24小时内每12小时口服50mg,再后以每次100mg,
In the second phase of the thrombolytic therapy for myocardial infarction (TTMI) trial, patients received intravenous infusion of recombinant tissue-type plasminogen activator (rt-PA) and were randomized to either conservative or invasive treatment. In our study, 1434 patients eligible for beta-blocker therapy were evaluated for immediate and delayed beta-blocker therapy, in which 720 were randomized to immediate-dosing and 714 to delayed dosing group. Immediate treatment group given metoprolol within 2 hours of rt-PA (5mg intravenous injection every 6 minutes or more, at intervals of 2 minutes to a total of 15mg, followed by oral administration of 50mg every 12 hours within 24 hours after After each 100mg,